GSK, Zantac
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits in the United States that claimed its discontinued heartburn drug Zantac caused cancer.
GSK Settles Zantac Lawsuits for $2.2B, Analysts Now Shift Focus to Vaccines
The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the product liability cases regarding allegations that GSK’s heartburn drug could cause cancer.
GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
The company also agreed to pay $70 million to settle a whistleblower lawsuit
GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac heartburn medication caused cancer.
GSK says $2.2bn settlement resolves most Zantac litigation
GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the settlements, which will be funded through "existing resources," and said there will be "no changes to GSK's growth agenda or investment plans for R&D as a result."
GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% of the Zantac (ranitidine) lawsuits currently pending against the company.
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
FiercePharma2d
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...
UK property market strengthens, but renters face tighter squeeze; GSK’s shares surge after $2.2bn Zantac settlement – business live
Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again ...